2022 World Conference on Lung Cancer (ePosters)-EP05.02-002. Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?

EP05.02-002. Who Benefits More of Durvalumab after Chemoradiotherapy (CRT) in Real-World Patients with Locally Advanced Non-Small-Cell Lung Cancer (NSCLC)?

Back to course

Pdf Summary

A study was conducted at the Hospital of Leon in Spain to analyze the effectiveness of durvalumab as consolidation therapy for locally advanced non-small-cell lung cancer (NSCLC) patients who had undergone chemoradiotherapy (CRT). The study included 37 patients treated with durvalumab between March 2018 and October 2021. The objective was to explore the clinical factors that may be associated with the benefit from durvalumab.<br /><br />The results showed that durvalumab consolidation therapy was effective in the patient population studied. The median progression-free survival (PFS) was 17 months, and the median overall survival (OS) was 29.9 months. The PFS at 12 and 24 months was 62% and 40% respectively, while the OS at 12 and 24 months was 87% and 74.5% respectively.<br /><br />One potentially predictive factor for the benefit of durvalumab was identified as the neutrophil-to-lymphocyte ratio (NLR) after CRT. Patients with a low NLR had a significantly better overall survival compared to those with a high NLR. This suggests that NLR may be a useful biomarker for identifying patients who may benefit more from durvalumab.<br /><br />The study also examined the incidence of radiation pneumonitis in patients receiving durvalumab. It was found that 57% of patients experienced any grade of radiation pneumonitis, while 20% experienced grade 3 pneumonitis.<br /><br />Overall, the study demonstrates the effectiveness of durvalumab consolidation therapy in real-world patients with locally advanced NSCLC. It highlights the potential use of NLR as a predictive factor for the benefit of durvalumab. These findings contribute to the understanding of the clinical factors that may influence the response to durvalumab treatment in this patient population.

Asset Subtitle

Blanca Távara

Meta Tag

Speaker Blanca Távara

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

Hospital of Leon

durvalumab

consolidation therapy

locally advanced non-small-cell lung cancer

NSCLC

chemoradiotherapy

progression-free survival

overall survival

neutrophil-to-lymphocyte ratio

radiation pneumonitis